Poop pills may protect kidney cancer patients from toxic drug reactions
NCT ID NCT04163289
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 21 times
Summary
This early-phase study tests whether giving kidney cancer patients a fecal microbiota transplant (FMT) before and during immunotherapy can prevent severe side effects like colitis. About 20 adults with advanced kidney cancer will receive FMT alongside the drugs ipilimumab and nivolumab. The goal is to see if this approach is safe and helps patients stay on treatment longer for better outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
London Regional Cancer Program of the Lawson Health Research Institute
London, Ontario, N6A 5W9, Canada
Conditions
Explore the condition pages connected to this study.